EAPCI: Biodegradable Scaffolds-Writers 2016
|
|
|
- Bruce Hawkins
- 5 years ago
- Views:
Transcription
1 Baumbach Andreas Byrne Robert - Medicines Company : Drugs (2015) - Abbott Vascular : Stents (2015) - Abbott Vascular : Stent (2015) - Boston Scientific : Medical devices (2015) - Biotronik : Medical devices (2015) - B.Braun : Medical devices (2015) Capodanno Davide - Aspen : Antithrombotic drug (2015) - Astra Zeneca : Antithrombotic drugs (2015) - Eli Lilly/Daiichi Sankyo : Antithrombotic drugs (2015) - Abbott Vascular : Mitral valve repair (2015) - Cordis : Stents (2015) - Stentys : Stents (2015) Escaned Javier - Astra Zeneca : Antiplatelet agents (2015) - Volcano : Coronary physiology, intravascular ultrasound (2015) - Abbott : Coronary stents (2015) - Medtronic : Coronary stents (2015) - Boston Scientific : Intravascular ultrasound, coronary stents (2015) Haude Michael - Lilly : anti platelet therapy (2015) - Abbott : BVS, MitraClip (2015) - Volcano : IVUS (2015) 1/5
2 Haude Michael - Biotronik : PCI (2015) - Cardiac Dimensions : structual heart interventions (2015) - Abbott : scaffold (2015) - Biotronik : scaffold (2015) - Cardiac Dimensions : structural heart intervention (2015) James Stefan - Bayer : anti coagulation (2015) - Astra Zeneca : platelet inhibition (2015) - The Medicines Company : anti coagulation (2015) - Astra Zeneca : Anti platelet (2015) - Abbot Vascular : stents (2015) Joner Michael - Orbus Neich : Combo (2015) - Biotronik : Magmaris (2015) - Astra Zeneca : Ticagrelor (2015) Juni Peter E - Research funding (personal). - European Society of Cardiology : Research Grant (2015) - see below : see below (2015) - Astra Zeneca : Coronary Artery Disease (2015) - Biosensors : Coronary Artery Disease (2015) - Eli Lilly : Coronary Artery Disease (2015) - Biotronik : Coronary Artery Disease (2015) 2/5
3 Juni Peter - Medicines Company : Coronary Artery Disease (2015) Kastrati Adnan Nothing to be declared (2015) Oktay Semih Nothing to be declared (2015) Onuma Yoshinobu Serruys Patrick - Abbott Vascular : PCI (2015) - Société Europa Digital & Publishing : Chief Editor (2015) - Astra Zeneca : Consultant (2015) - Medtronic : Consultant (2015) - Biotronik : Consultant (2015) - Abbott Laboratories : consultant (2015) - Volcano : Consultant (2015) - GLG research : Consultant (2015) - Sinomedical Sciences Technology China : Consultant (2015) - Stentys France : Consultant (2015) - Svelte Medical Systems : Consultant (2015) - Cardialysis : Consultant/Chairman Scientific Advisory Board (2015) Stefanini Giulio - Biotronik : Interventional Cardiology (2015) - Medicines Company : Interventional Cardiology (2015) - B.Braun : Interventional Cardiology (2015) Wijns William - Biosensors : device (2015) - Boston Scientific : device (2015) 3/5
4 Wijns William - Medtronic : device (2015) - St Jude Medical : device (2015) - Biotronik : device (2015) - Terumo Inc : device (2015) - Abbott Vascular : device (2015) - MICELL : device (2015) - Stentys : device (2015) - Celyad (former Cardio3BioSciences) : cell therapy (2015) - Boston Scientific : device (2015) - Medtronic : device (2015) - St Jude Medical : device (2015) - Biotronik : device (2015) - Abbott Laboratories : device (2015) - MICELL : device (2015) - Microport : device (2015) Windecker Stephan - Astra Zeneca : Antiplatelet therapy (2015) - Daiichi Sankyo : Antiplatelet therapy (2015) - Boston Scientific : Complex PCI (2015) - Sanofi Aventis : Managing Dyslipidemia (2015) - Sorin Group : Electrophysiology (2015) - Biotronik : Electrophysiology (2015) 4/5
5 Windecker Stephan - Johnson & Johnson : Electrophysiology and PCI (2015) - Guerbet : Imaging (2015) - Novartis : IMP (2015) - Actelion : IMP (2015) - Medicines Company : IMP (2015) - Merck Sharp & Dohme : IMP (2015) - St Jude Medical : PCI (2015) - Abbott : PCI and Structural Heart Disease (2015) - Boston Scientific : Structural Heart Disease (2015) - Edwards Lifesciences : Structural Heart Disease (2015) - Symetis SA : Structural Heart Disease (2015) - Medtronic : Structural Heat Disease (2015) 5/5
Patrick W. Serruys MD. PhD. 1 Bernard Chevalier MD. 2 Yoshinobu Onuma MD. PhD. 3 on behalf of ABSORB II investigators
TCT 216, Washington convention center October 3 th 216, 8:3 am- Room 159 Level 1 Late breaking clinical trial and First report investigations Press Conf.1 ABSORB II: Three-year Clinical Outcomes from a
Bioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
Additional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors
Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors Agewall Stefan - Astra Zeneca : Platelet inhibition Bassand Jean-Pierre - Glaxo Smith Kline : fondaparinux - Lilly : prasugrel
Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors
Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors Achenbach Stephan - Siemens Healthcare : CT (2010-2011-2012) - Servier : Imaging (2010-2011-2012) - Guerbet : Imaging (2010-2011-2012)
Biodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Biodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention A Pooled Analysis of Individual Patient Data from ISAR-TEST
Cost-Effectiveness of PCI with Drug Eluting Stents vs. Bypass Surgery for Patients with Diabetes and Multivessel CAD: Results from the FREEDOM Trial
Cost-Effectiveness of PCI with Drug Eluting Stents vs. Bypass Surgery for Patients with Diabetes and Multivessel CAD: Results from the FREEDOM Trial Elizabeth A. Magnuson, Valentin Fuster, Michael E. Farkouh,
Technical Aspects and Clinical Indications of FFR
Technical Aspects and Clinical Indications of FFR Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst - OLV Clinic Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on
2017 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members
2017 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members Baumgartner Helmut - Gore : Occluders for shunt closure (2015) - St. Jude Medical : Occluders for shunt closure
Gestione della DAPT post-pci in chirurgia cardiaca e non cardiaca
Gestione della DAPT post-pci in chirurgia cardiaca e non cardiaca Francesco Saia Polo Cardio-Toraco-Vascolare Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola Malpighi Bologna DISCLOSURE
Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors
Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors Alfieri Ottavio Andreotti Felicita Antunes Manuel J - Valtech : Mitral products (2011) - Edwards Lifesciences : Prosthetic
Focus on Acute Coronary Syndromes
Focus on Acute Coronary Syndromes Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on my behalf go to the Cardiovascular
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Chairpersons Christian W. Hamm Medical Clinic
A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
Speaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
Guidelines on NSTE-ACS (version 2015) - Task Force
Guidelines on NSTE-ACS (version 2015) - Task Force Andreotti Felicita - Pfizer (see also BMS) : apixaban (2012-2013) - BMS-Pfizer : apixaban, cardiovascular metabolism (2012-2013) - Bayer Schering Pharma
EAPCI 2018 Expert Consensus Document on Clinical Use of Intracoronary Imaging Giulio Guagliumi, MD FESC
EAPCI 2018 Expert Consensus Document on Clinical Use of Intracoronary Imaging Giulio Guagliumi, MD FESC EAPCI Scientific Document Committee Robert Byrne, MD Davide Capodanno, MD Motivation The clinical
REPORT OF THE ESC-EAPCI TASK FORCE ON THE EVALUATION AND USE OF BIORESORBABLE SCAFFOLDS FOR PERCUTANEOUS CORONARY INTERVENTION
THE EVALUATION AND USE OF BIORESORBABLE SCAFFOLDS FOR PERCUTANEOUS CORONARY INTERVENTION Task Force Members: Robert A. Byrne (DE), Giulio G. Stefanini (IT), Davide Capodanno (IT), Yoshinobu Onuma (NL),
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST In the last five years, I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik,
NCDR.17 Poster Abstract Reviewers
NCDR.17 Poster Abstract Reviewers Name Anderson, Cornelia Armstrong, Ehrin J., MD Attaran, Robert, MD Beatty, Alexis Blankenship, James, MD Bonner, David Bradley, Steve Casey, Patricia Cha, Yong-Mei, MD
Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
Department of Medicine III, Martin Luther-University Halle, Germany b. Unità Operativa di Cardiologia, Ospedale Maggiore, Bologna, Italy c
Comparison of CHADS 2 -Score with CHA 2 DS 2 VASc-Score in a prospective multicenter registry on patients with atrial fibrillation undergoing coronary artery stenting -First results from the AFCAS-trial-
Roxana Mehran, Dominick J. Angiolillo, Ron Waksman, Joseph M. Sweeny, Ganesh Raveendran, Renli Teng, Yonggang Zhao, Glenn Carlson NCT
Ticagrelor versus Clopidogrel in Troponinnegative Patients with Acute Coronary Syndrome Undergoing Ad-Hoc Percutaneous Coronary Intervention: Results of a Prospective, Randomized, Multicenter Pharmacodynamic
2018 ESC/EACTS Guidelines on myocardial revascularization - Task Force
2018 ESC/EACTS Guidelines on myocardial revascularization - Task Force Ahlsson Anders - Sanofi Aventis : Atrial fibrillation symposium speakers fee year 2008: 500 Euro (2016-2017) D - Research funding
Organizational, or Other Financial Benefit None None None None None None. None None None None None None
Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor
Double-Dose Clopidogrel in ACS: The CURRENT/OASIS-7 Trial
Double-Dose Clopidogrel in ACS: The CURRENT/OASIS-7 Trial David J. Cohen, M.D., M.Sc. Director, Cardiovascular Research Saint-Luke s Mid America Heart Institute Professor of Medicine University of Missouri-Kansas
Bernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience
DOI 10.1007/s40119-015-0050-2 BRIEF REPORT Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience Jeffrey E. Rossi. Andrew Noll. Brian Bergmark. James M. McCabe.
TREATMENT OF SECONDARY MITRAL REGURGITATION VIA PERCUTANEOUS ANNULOPLASTY
TREATMENT OF SECONDARY MITRAL REGURGITATION VIA PERCUTANEOUS ANNULOPLASTY This symposium took place on 21st May 215 (13:35-14:35), as part of EuroPCR 215; the official annual meeting of the European Association
Bern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
STEMI Linee guida ESC Maddalena Lettino, Italy
STEMI Linee guida ESC 2017 Maddalena Lettino, Italy Disclosure Speaker fee: Aspen, Astra Zeneca, BMS, Boehringer, Eli Lilly, DaichiiSankio, Bayer, Pfizer, Sanofi Advisory board member: Astra Zeneca, Eli
ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors
ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Agewall Stefan - Astra Zeneca : Platelet inhibition Alegria Ezquerra Eduardo - Roche : dabigatran
WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up Ron Waksman, MD FACC FSCAI FESC Professor of Medicine, Georgetown University Director, Cardiovascular Research
ESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
DES in primary PCI for STEMI: contra
DES in primary PCI for STEMI: contra Philippe Gabriel Steg Department of Cardiology Hôpital Bichat Claude Bernard, AP-HP Université Paris VII Denis Diderot INSERM U-698 Paris, France Ph. Gabriel Steg -
Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
The Universal Definition of Myocardial Infarction 3 rd revision, 2012
The Universal Definition of Myocardial Infarction 3 rd revision, 2012 Joseph S. Alpert, MD Professor of Medicine, University of Arizona College of Medicine, Tucson, AZ; Editor-in-Chief, American Journal
Bernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
HKSTENT 2012: 2012/3/3-4 11:47 12:17 CTO Complication
HKSTENT 2012: 2012/3/3-4 11:47 12:17 CTO Complication SATORU SUMITSUJI MD. FACC. Specially Appointed Associate Professor Advanced Cardiovascular Therapeutics, Osaka University Director of Heart Center,
6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.
Journal of the American College of Cardiology Vol. 58, No. 3, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.052
Cardiac Bone Marrow Cell Injection for Chronic Ischemic Heart Disease
Cardiac Bone Marrow Cell Injection for Chronic Ischemic Heart Disease Monique R.M. Jongbloed 070303 Beeres Boek.indb 1 06-09-2007 17:13:27 The studies described in this thesis were performed at the Department
Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
Abstract Aims: This study evaluated the views of the cardiology community on the clinical use of coronary intravascular CLINICAL RESEARCH
CLINICAL RESEARCH Current use of intracoronary imaging in interventional practice Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force Blom Nico Nothing to be declared (2012-2013-2014-2015) Blomstrom-Lundqvist Carina - Sanofi Aventis : AF (2012) - Bayer : atrial fibrillation
Freedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
Jose Mª de la Torre Hernandez, MD, PhD, FESC. Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander. SPAIN
Validation and application of IVUS-MLA in LMCA disease Jose Mª de la Torre Hernandez, MD, PhD, FESC Interventional Cardiology Dpt Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander.
2018 ESC Guidelines for the diagnosis and management of syncope - Task Force Members
2018 ESC Guidelines for the diagnosis and management of syncope - Task Force Members Brignole Michele Nothing to be declared (2015-2016-2017) de Lange Frederik Nothing to be declared (2015-2016-2017) Deharo
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
Antithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
Guidelines on Pericardial Diseases 2015 (TF18) - Task Force
Guidelines on Pericardial Diseases 2015 (TF18) - Task Force Adler Yehuda Nothing to be declared (2013-2014-2015) Badano Luigi Paolo - SamsungMedison : Ultrasound (2013) - Edwards Lifesciences : Clinical
CLINICAL RESEARCH Coronary artery disease
European Heart Journal (2016) 37, 2701 2709 doi:10.1093/eurheartj/ehw196 CLINICAL RESEARCH Coronary artery disease Sustained safety and performance of the second-generation drug-eluting absorbable metal
Joo-Yong Hahn, MD/PhD
Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
Myocardial injury, necrosis and infarction
Myocardial injury, necrosis and infarction Harvey White Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Faculty Disclosure In accordance
Guidelines on Aortic Disease 2014 (TF05) - TF Members
Guidelines on Aortic Disease 2014 (TF05) - TF Members Aboyans Victor None declared (2011-2012-2013) - Pfizer : Anticoagulation (2014) - Bayer AG : Anticoagulation (2014) - Merck Sharp & Dohme : Dyslipidemia
STEMI Care 2014 at the Crossroads: Taking the right road
STEMI Care 2014 at the Crossroads: Taking the right road Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Vice President, The Canadian Association of Interventional Cardiology Director,
Echocardiographic evaluation of left ventricular function in ischemic heart disease. Sjoerd A. Mollema
Echocardiographic evaluation of left ventricular function in ischemic heart disease Sjoerd A. Mollema The studies described in this thesis were performed at the Department of Cardiology of the Leiden University
Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,
Antiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS
Antiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS Is There Still a Role for IV Antiplatelet Agents (Cangrelor, GPIIbIIIA inhibitors)? François Schiele, MD, PhD Department of Cardiology, University
The Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
Journal of the American College of Cardiology
Advertisement Journal of the American College of Cardiology Volume 72, Issue 3, July 2018 DOI: 10.1016/j.jacc.2018.04.063 PDF Article Download Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory
France Interventional Cardiology Market Outlook to 2020
France Interventional Cardiology Market Outlook to 2020 Reference Code: GDMECC0358DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
U.S. Markets for Interventional Cardiology Products
U.S. Markets for Interventional Cardiology Products Table of Contents EXECUTIVE SUMMARY... ES-1 i. Diagnostic Interventional Cardiology Products... ES-2 ii. Therapeutic Interventional Cardiology Products...
Impact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 3, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.11.011 CLINICAL RESEARCH
Devilish Definitions: Bleeding, Procedural Outcomes and Other Key Endpoints/Variables. US ACADEMIC View
Devilish Definitions: Bleeding, Procedural Outcomes and Other Key Endpoints/Variables US ACADEMIC View Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Shifting the
P2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
Update Guidelines in STEMI Management: Focus on Logistic and System Approach to Reperfusion Therapy
March 14 th, 2018 The First Asia Forum in Emergency Medicine BNH Hospital, Bangkok, Thailand Update Guidelines in STEMI Management: Focus on Logistic and System Approach to Reperfusion Therapy Wacin Buddhari,
Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
Journal of the American College of Cardiology Vol. 62, No. 3, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 62, No. 3, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.04.043
DAPT Essential Messages from ESC Guidelines. Committee for Practice Guidelines
2017 Essential Messages from ESC Guidelines Committee for Practice Guidelines DAPT Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Essential Messages 2017 ESC focused update on dual
Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and
Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American
2-Year Patient-Related Versus Stent-Related Outcomes
Journal of the American College of Cardiology Vol. 60, No. 13, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004
Drug Eluting Stents overhyped, overused and overpriced?
Advanced Angioplasty 2008 BCIS 23 rd Jan 2008 Drug Eluting Stents overhyped, overused and overpriced? William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be
The COMFORTABLE AMI Randomized Trial JAMA. 2012;308(8):
ORIGINAL CONTRIBUTION Effect of Biolimus-Eluting With Biodegradable Polymer vs Bare-Metal on Cardiovascular Events Among Patients With Acute Myocardial Infarction The COMFORTABLE AMI Randomized Trial Scan
CORPORATE SUPPORT. AstraZeneca
CORPORATE SUPPORT The 28 th Annual Cardiovascular Interventions is supported, in part, by educational grants and exhibits from industry, in accordance with the ACCME Accreditation Standards for Commercial
2016 ESC Guidelines for the Diagnosis and treatment of Acute & Chronic Heart Failure
2016 ESC Guidelines for the Diagnosis and treatment of Acute & Chronic Heart Failure AHF - Initial phase in the emergency department: diagnosis and management Héctor Bueno, MD, PhD, FESC, FAHA Department
Subsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
Magmaris: the impact of scaffold design and materials on reducing thrombogenicity
: the impact of scaffold design and materials on reducing thrombogenicity Michael Joner, MD Deutsches Herzzentrum München und Deutsches Zentrum für Herz-Kreislaufforschung e.v. Potential conflicts of interest
XXI Congress of the Cardiology Society of Serbia (CSS) Preliminary Programme Zlatibor, October, 2017
XXI Congress of the Cardiology Society of Serbia () Preliminary Programme Zlatibor, 19-22 October, 15.00 Interventional Cardiology in Serbia 15.15 15.30 15.45 16.00 16.15 at the Congress Thursday, October
ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
2018 ESC Guidelines for the diagnosis and management of syncope - Task Force
2018 ESC Guidelines for the diagnosis and management of syncope - Task Force Brignole Michele de Lange Frederik Deharo Jean-Claude Nothing to be declared (2015-2016-2017) Nothing to be declared (2015-2016-2017)
Individualized antithrombotic therapy
Review 26 Individualized antithrombotic therapy T. F. Lüscher ; J. Steffel 2 Department of Cardiology, University Heart Center, University Hospital, Zurich, Switzerland; 2 Center for Molecular Cardiology,
Bioprosthetic Valve Fracture for Optimizing Results of Valve-in-Valve TAVR
Bioprosthetic Valve Fracture for Optimizing Results of Valve-in-Valve TAVR David J. Cohen, M.D., M.Sc. Director, Cardiovascular Research Saint-Luke s Mid America Heart Institute Professor of Medicine University
J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions
Type of Relationship with Industry
in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force Aboyans Victor - Sanofi Aventis : Hyperlipidemia (2015) - Novartis : Hypertension (2015-2016) - Boehringer-Ingelheim
PCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
Coronary Reperfusion. & Secondary Prevention. Oberlech, Austria April 14 19, 2007 H. DARIUS K. HUBER A. M. ROSS P R O R A A ORGANIZERS:
Coronary Reperfusion & Secondary Prevention ORGANIZERS: H. DARIUS K. HUBER A. M. ROSS Oberlech, Austria April 14 19, 2007 TOPICS: Acute Coronary Syndromes Antithrombins Antiplatelet Therapy ASD+PFO Closure
Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
Journal of the American College of Cardiology Vol. 61, No. 20, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 61, No. 20, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.036
ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
European Society of Cardiology Hotline Stockholm - Zone K 31 st August 2010 Placebo ARB Kumagai K, et al. JACC 2003 Discussant ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial